Wednesday, August 20, 2014 6:54:16 PM
Re; ARRY/NVS and potential return of MEK162
Really a tricky issue all around.
If this is just a straight up commercial decision by NVS not to develop a "second" MEK, then this could be a great opportunity for ARRY. They will have full rights to a drug with financial support through 3 P3s and numerous expansion P2s. They can either keep the entire drug or re-partner on better terms (likely a decent chunk of cash up front along with US 50% profit split and 15+% royalty ex US).
On the other hand, one always must assume a decision to return a drug is at least partly based on data we do not see.
I think I need to both buy more and sell at the same time
Really a tricky issue all around.
If this is just a straight up commercial decision by NVS not to develop a "second" MEK, then this could be a great opportunity for ARRY. They will have full rights to a drug with financial support through 3 P3s and numerous expansion P2s. They can either keep the entire drug or re-partner on better terms (likely a decent chunk of cash up front along with US 50% profit split and 15+% royalty ex US).
On the other hand, one always must assume a decision to return a drug is at least partly based on data we do not see.
I think I need to both buy more and sell at the same time
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
